Amendment AA3-SB70

SB70-AA3,80,5 1. One member representing the University of Wisconsin School of Medicine and Public Health.

SB70-AA3,80,6 2. One member representing the Medical College of Wisconsin.

SB70-AA3,80,7 3. One member who has a spinal cord injury.

SB70-AA3,80,8 4. One member who is a family member of a person with a spinal cord injury.

SB70-AA3,80,9 5. One member who is a veteran who has a spinal cord injury.

SB70-AA3,80,11 6. One member who is a physician specializing in the treatment of spinal cord injuries.

SB70-AA3,80,12 7. One member who is a researcher in the field of neurosurgery.

SB70-AA3,80,14 8. One member who is a researcher employed by the veterans health administration of the U.S. department of veterans affairs.

SB70-AA3,80,17 (b) If the department of health services is unable to appoint a member specified in par. (a) 1. to 8., the department of health services may appoint a member representing the general public in lieu of the member so specified.

SB70-AA3,77 Section 77. 255.45 of the statutes is created to read:

SB70-AA3,80,20 255.45 Spinal cord injury research grants and symposia. (1) Definitions. In this section:

SB70-AA3,80,21 (a) “Council” means the spinal cord injury council.

SB70-AA3,80,22 (b) “Grant program” means the program established under sub. (2).

SB70-AA3,81,5 (2) Grant program. The department shall establish a program to award grants, from the appropriation under s. 20.435 (1) (b), to persons in this state for research into spinal cord injuries. The purpose of the grants is to support research into new and innovative treatments and rehabilitative efforts for the functional improvement of people with spinal cord injuries, and research topics may include pharmaceutical, medical device, brain stimulus, and rehabilitative approaches and techniques. Grant recipients shall agree to present their research findings at symposia held by the department under sub. (3).

SB70-AA3,81,8 (3) Symposia. The department may hold symposia every 2 years for recipients of grants under the grant program to present findings of research supported by the grants.

SB70-AA3,81,12 (4) Grant reports. By January 15 of each year, the department shall submit an annual report to the appropriate standing committees of the legislature under s. 13.172 (3) that identifies the recipients of grants under the grant program and the purposes for which the grants were used.

SB70-AA3,81,13 (5) Council. (a) The council shall do all of the following:

SB70-AA3,81,15 1. Develop criteria for the department to evaluate and award grants under the grant program.

SB70-AA3,81,17 2. Review and make recommendations to the department on applications submitted under the grant program.

SB70-AA3,81,18 3. Perform other duties specified by the department.

SB70-AA3,81,22 (b) Each member of the council shall disclose in a written statement any financial interest in any organization that the council recommends to receive a grant under the grant program. The council shall include the written statements with its recommendations to the department on grant applications.

SB70-AA3,9119 Section 9119. Nonstatutory provisions; Health Services

SB70-AA3,82,3 (1) Spinal cord injury council; initial appointments. Notwithstanding the length of terms specified for the members of the spinal cord injury council under s. 15.197 (20) (a) (intro.), initial appointments to the council shall be made as follows:

SB70-AA3,82,6 (a) The members appointed under s. 15.197 (20) (a) 1., 3., 5., and 7., or in lieu of those members under s. 15.197 (20) (b), shall be appointed for terms expiring on July 1, 2025.

SB70-AA3,82,9 (b) The members appointed under s. 15.197 (20) (a) 2., 4., 6., and 8., or in lieu of those members under s. 15.197 (20) (b), shall be appointed for terms expiring on July 1, 2026.”.

SB70-AA3,82,10 205. Page 374, line 11: after that line insert:

SB70-AA3,82,11 “ Section 78. 15.07 (3) (bm) 7. of the statutes is created to read:

SB70-AA3,82,13 15.07 (3) (bm) 7. The prescription drug affordability review board shall meet at least 4 times each year.

SB70-AA3,79 Section 79. 15.735 of the statutes is created to read:

SB70-AA3,82,17 15.735 Same; attached board. (1) There is created a prescription drug affordability review board attached to the office of the commissioner of insurance under s. 15.03. The board shall consist of the following members:

SB70-AA3,82,18 (a) The commissioner of insurance or his or her designee.

SB70-AA3,82,22 (b) Two members appointed for 4-year terms who represent the pharmaceutical drug industry, including pharmaceutical drug manufacturers and wholesalers. At least one of the members appointed under this paragraph shall be a licensed pharmacist.

SB70-AA3,82,24 (c) Two members appointed for 4-year terms who represent the health insurance industry, including insurers and pharmacy benefit managers.

SB70-AA3,83,3 (d) Two members appointed for 4-year terms who represent the health care industry, including hospitals, physicians, pharmacies, and pharmacists. At least one of the members appointed under this paragraph shall be a licensed practitioner.

SB70-AA3,83,5 (e) Two members appointed for 4-year terms who represent the interests of the public.

SB70-AA3,83,8 (2) A member appointed under sub. (1), except for a member appointed under sub. (1) (b), may not be an employee of, a board member of, or a consultant to a drug manufacturer or trade association for drug manufacturers.

SB70-AA3,83,13 (3) Any conflict of interest, including any financial or personal association, that has the potential to bias or has the appearance of biasing an individual's decision in matters related to the board or the conduct of the board's activities shall be considered and disclosed when appointing that individual to the board under sub. (1).

SB70-AA3,80 Section 80. Subchapter VI (title) of chapter 601 [precedes 601.78] of the statutes is created to read:

SB70-AA3,83,16 CHAPTER 601

SB70-AA3,83,18 SUBCHAPTER VI Prescription drug

SB70-AA3,83,19 affordability review board

SB70-AA3,81 Section 81. 601.78 of the statutes is created to read:

SB70-AA3,83,21 601.78 Definitions. In this subchapter:

SB70-AA3,83,23 (1) “Biologic” means a drug that is produced or distributed in accordance with a biologics license application approved under 21 CFR 601.20.

SB70-AA3,83,25 (2) “Biosimilar” means a drug that is produced or distributed in accordance with a biologics license application approved under 42 USC 262 (k) (3).

SB70-AA3,84,2 (3) “Board” means the prescription drug affordability review board established under s. 15.735 (1).

SB70-AA3,84,5 (4) “Brand name drug” means a drug that is produced or distributed in accordance with an original new drug application approved under 21 USC 355 (c), other than an authorized generic drug, as defined in 42 CFR 447.502.

SB70-AA3,84,8 (5) “Financial benefit” includes an honorarium, fee, stock, the value of the stock holdings of a member of the board or any immediate family member, and any direct financial benefit deriving from the finding of a review conducted under s. 601.79.

SB70-AA3,84,9 (6) “Generic drug” means any of the following:

SB70-AA3,84,11 (a) A retail drug that is marketed or distributed in accordance with an abbreviated new drug application approved under 21 USC 355 (j).

SB70-AA3,84,12 (b) An authorized generic drug, as defined in 42 CFR 447.502.

SB70-AA3,84,14 (c) A drug that entered the market prior to 1962 and was not originally marketed under a new drug application.

SB70-AA3,84,17 (7) “Immediate family member” means a spouse, grandparent, parent, sibling, child, stepchild, or grandchild or the spouse of a grandparent, parent, sibling, child, stepchild, or grandchild.

SB70-AA3,84,18 (8) “Manufacturer” means an entity that does all of the following:

SB70-AA3,84,21 (a) Engages in the manufacture of a prescription drug product or enters into a lease with another manufacturer to market and distribute a prescription drug product under the entity's own name.

SB70-AA3,84,23 (b) Sets or changes the wholesale acquisition cost of the prescription drug product described in par. (a).

SB70-AA3,84,24 (9) “Pharmacy benefit manager” has the meaning given in s. 632.865 (1) (c).

SB70-AA3,85,2 (10) “Prescription drug product” means a brand name drug, a generic drug, a biologic, or a biosimilar.

SB70-AA3,82 Section 82. 601.785 of the statutes is created to read:

SB70-AA3,85,8 601.785 Prescription drug affordability review board. (1) Mission. The purpose of the board is to protect state residents, the state, local governments, health plans, health care providers, pharmacies licensed in this state, and other stakeholders of the health care system in this state from the high costs of prescription drug products.

SB70-AA3,85,9 (2) Powers and duties. (a) The board shall do all of the following:

SB70-AA3,85,12 1. Meet in open session at least 4 times per year to review prescription drug product pricing information, except that the chair may cancel or postpone a meeting if there is no business to transact.

SB70-AA3,85,14 2. To the extent practicable, access and assess pricing information for prescription drug products by doing all of the following:

SB70-AA3,85,17 a. Accessing and assessing information from other states by entering into memoranda of understanding with other states to which manufacturers report pricing information.

SB70-AA3,85,18 b. Assessing spending for specific prescription drug products in this state.

SB70-AA3,85,19 c. Accessing other available pricing information.

SB70-AA3,85,20 (b) The board may do any of the following:

SB70-AA3,85,21 1. Promulgate rules for the administration of this subchapter.

SB70-AA3,86,2 2. Enter into a contract with an independent 3rd party for any service necessary to carry out the powers and duties of the board. Unless written permission is granted by the board, any person with whom the board contracts may not release, publish, or otherwise use any information to which the person has access under the contract.

SB70-AA3,86,5 (c) The board shall establish and maintain a website to provide public notices and make meeting materials available under sub. (3) (a) and to disclose conflicts of interest under sub. (4) (d).

SB70-AA3,86,9 (3) Meeting requirements. (a) Pursuant to s. 19.84, the board shall provide public notice of each board meeting at least 2 weeks prior to the meeting and shall make the materials for each meeting publicly available at least one week prior to the meeting.

SB70-AA3,86,12 (b) Notwithstanding s. 19.84 (2), the board shall provide an opportunity for public comment at each open meeting and shall provide the public with the opportunity to provide written comments on pending decisions of the board.

SB70-AA3,86,15 (c) Notwithstanding subch. V of ch. 19, any portion of a meeting of the board concerning proprietary data and information shall be conducted in closed session and shall in all respects remain confidential.

SB70-AA3,86,17 (d) The board may allow expert testimony at any meeting, including when the board meets in closed session.

SB70-AA3,86,21 (4) Conflicts of interest. (a) A member of the board shall recuse himself or herself from a decision by the board relating to a prescription drug product if the member or an immediate family member has received or could receive any of the following:

SB70-AA3,86,23 1. A direct financial benefit deriving from a determination, or a finding of a study or review, by the board relating to the prescription drug product.

SB70-AA3,87,3 2. A financial benefit in excess of $5,000 in a calendar year from any person who owns, manufactures, or provides a prescription drug product to be studied or reviewed by the board.

SB70-AA3,87,7 (b) A conflict of interest under this subsection shall be disclosed by the board when hiring board staff, by the appointing authority when appointing members to the board, and by the board when a member of the board is recused from any decision relating to a review of a prescription drug product.

SB70-AA3,87,11 (c) A conflict of interest under this subsection shall be disclosed no later than 5 days after the conflict is identified, except that, if the conflict is identified within 5 days of an open meeting of the board, the conflict shall be disclosed prior to the meeting.

SB70-AA3,87,15 (d) The board shall disclose a conflict of interest under this subsection on the board's website unless the chair of the board recuses the member from a final decision relating to a review of the prescription drug product. The disclosure shall include the type, nature, and magnitude of the interests of the member involved.

SB70-AA3,87,18 (e) A member of the board or a 3rd-party contractor may not accept any gift or donation of services or property that indicates a potential conflict of interest or has the appearance of biasing the work of the board.

SB70-AA3,83 Section 83. 601.79 of the statutes is created to read:

SB70-AA3,87,21 601.79 Drug cost affordability review. (1) Identification of drugs. The board shall identify prescription drug products that are any of the following:

SB70-AA3,87,25 (a) A brand name drug or biologic that, as adjusted annually to reflect adjustments to the U.S. consumer price index for all urban consumers, U.S. city average, as determined by the U.S. department of labor, has a launch wholesale acquisition cost of at least $30,000 per year or course of treatment.

SB70-AA3,88,4 (b) A brand name drug or biologic that, as adjusted annually to reflect adjustments to the U.S. consumer price index for all urban consumers, U.S. city average, as determined by the U.S. department of labor, has a wholesale acquisition cost that has increased at least $3,000 during a 12-month period.

SB70-AA3,88,7 (c) A biosimilar that has a launch wholesale acquisition cost that is not at least 15 percent lower than the referenced brand biologic at the time the biosimilar is launched.

SB70-AA3,88,11 (d) A generic drug that has a wholesale acquisition cost, as adjusted annually to reflect adjustments to the U.S. consumer price index for all urban consumers, U.S. city average, as determined by the U.S. department of labor, that meets all of the following conditions:

SB70-AA3,88,17 1. Is at least $100 for a supply lasting a patient for a period of 30 consecutive days based on the recommended dosage approved for labeling by the federal food and drug administration, a supply lasting a patient for a period of fewer than 30 days based on the recommended dosage approved for labeling by the federal food and drug administration, or one unit of the drug if the labeling approved by the federal food and drug administration does not recommend a finite dosage.

SB70-AA3,88,20 2. Increased by at least 200 percent during the preceding 12-month period, as determined by the difference between the resulting wholesale acquisition cost and the average of the wholesale acquisition cost reported over the preceding 12 months.